UNSPSC 51263122: Esmolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C16H25NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MDY902UXSR, chemically known as benzenepropanoic acid, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-, methyl ester but generally known as esmolol, which bears US NIH Compound Identifier 59768. European Medicines Agency schedules Esmolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13718MIG.

UNSPSC 51263122 Esmolol is a Commodity code that identifies a specific pharmaceutical product — a beta-blocker used in acute-care settings for rapid blood-pressure control. State and local governments procure esmolol primarily through county health departments and regional health authorities as part of emergency medical services, hospital formulary stocking, and community health program procurement. The recent activity under this code shows state and local agencies buying esmolol alongside related pharmaceutical and medical products as part of broader health-system acquisitions rather than as isolated line items. Issuing bodies soliciting under this code span county health departments, state health and human services agencies, and regional public health authorities. Seminole County, Florida and the Texas Health and Human Services Commission represent the primary recent buyers, though the Texas HHS procurement is an exploratory RFI focused on direct-to-manufacturer pharmacy initiatives rather than a direct esmolol solicitation.

Geographic activity concentrates in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, requesting 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023 — a mismatch suggesting the opportunity record contains a data error. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for direct-to-manufacturer prescription programs with pharmaceutical manufacturers, with a response deadline of April 3, 2026. Neither opportunity names esmolol explicitly; the code shows minimal recent state and local activity tied directly to this pharmaceutical product. The actual procurement activity appears unrelated to esmolol's clinical scope — the Seminole County opportunity centers on naloxone and drug deactivation systems, while the Texas RFI addresses pharmacy benefit management structure rather than specific drug products.